


INVESTIGATION OF ELECTROPHILIC CYCLIZATION REACTIONS OF 2-(3-SUBSTITUTED 2-PROPYNYLTHIO) METHYL-1H-BENZIMIDAZOLES

Indrė Misiūnaitė, Rita Bukšnaitienė, Ieva Karpavičienė

Faculty of Chemistry and Geosciences, Vilnius University, Naugarduko 24, LT-03225, Vilnius, Lithuania
Indre.Misiunaite@gmail.com

Derivatives containing imidazo[2,1-c][1,4]thiazine fragment can be potential anti HSV-1 suppressor[1], β -lactamase inhibitor [2], anti trypanosomatid agents[3] and shows cytotoxic properties [4]. However, only several synthetic ways are used for this type of heterocycle [5]. One of the new routes to imidazothiazine could be through electrophile initiated heteroatom cyclization reaction of alkynes which is used in synthesis of other types of heterocycles [6]. In the literature there is no information about formation of imidazo[2,1-c][1,4]thiazine using propargylic substrates in any cyclization reactions. Hence, this is a new potential investigation field in organic chemistry. Keeping in mind that benzimidazoles and a lot of their derivatives are interesting due to their biological properties [7], we decided to synthesize various 2-(3-substituted 2-propynylthio) methyl-1H-benzimidazoles **1** and investigate their intramolecular electrophilic cyclization.

The starting materials **1** were prepared from 2-bromo-1-arylpropynes and (1H-benzo[d]imidazol-2-yl)methanethiol, with sodium hydroxide. Then the electrophile initiated cyclization reactions of propynythiomethylbenzimidazoles **1** were investigated. It was found that electrophile has a significant effect on the reaction results. Depending on electrophile it is possible to obtain thiazinobenzimidazole **2** derivatives or addition products **3** without cyclization. The scope and limitations of this reaction will be enlarged in presentation.



This research is funded by the European Social Fund under the No 09.3.3-LMT-K-712 "Development of Competences of Scientists, other Researchers and Students through Practical Research Activities" measure.



Kuriame
Lietuvos ateitį
2014–2020 metų
Europos Sąjungos
fondų investicijų
veiksmų programa

¹ S.A. Galal, S.I. El-Naem, A.O.H El-Nezhaway, M.A. Ali, H.I. El-Diwani, Arch. Pharm. Chem. Life Sci., 11, 2011, 255-263

² T.S. Mansour, P.A. Bradford, A.M. Venkatesan, Annual reports in medicinal chemistry 43, 2008 247 - 267

³ M. Boiani, L. Boiani, A. Denicola, S.T.de Ortiz, E.Serna, N. Vera de Bilbao, L. Sanabria, G. Yaluff, H. Nakayama, A.Rojas de Arias, C. Vega, M. Rolan, A. Gomez Barrio, H. Cerecetto, M. Gonza'lez, J. Med. Chem. 49, 2006, 3215-3224

⁴ M.E. Suh, M.J. Kang, S.Y. Park, Bioorg. Med. Chem., 9, 2001, 2987-2991

⁵ A. Chimirri, A.M. Monforte, P. Monforte, F. Nicolò, A. Rao, M. Zappalà, Heterocycles, 53, 2000, 613-620

⁶ B. Godoi, R.F. Schumacher, G. Zeni, Chem. Rev. 111, 2011, 2937-2980

⁷ F.A.S. Alasmay, A.M. Snelling, M.E. Zain, Ah.M. Alafeefy, A.S. Awaad, N. Karodia, Molecules, 20, 2015, 15206-15223